Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 8/20 | 0.70 |
| ▸ | CDK2 | P24941 | 8/20 | 0.70 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.70 |
| ▸ | CDK7 | P50613 | 12/20 | 0.67 |
| ▸ | CCNH | P51946 | 10/20 | 0.67 |
| ▸ | MNAT1 | P51948 | 10/20 | 0.67 |
| ▸ | CDK13 | Q14004 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789145 | 0.87 | CCNA2 (0.78) | CCNA2CDK2CCNA1 | |
| SCHEMBL6786532 | 0.87 | CCNA2 (0.78) | CCNA2CDK2CCNA1 | |
| SCHEMBL6783043 | 0.87 | CCNA2 (0.78) | CCNA2CDK2CCNA1 | |
| SCHEMBL28634298 | 0.86 | CCNA2 (0.70) | CCNA2CDK2CCNA1CDK7CCNH | |
| SCHEMBL18285130 | 0.85 | CDK7 (0.84) | CCNA2CDK2CCNA1CDK7CCNH | |
| SCHEMBL18284993 | 0.83 | CDK7 (0.65) | CCNA2CDK2CCNA1CDK7CCNH | |
| SCHEMBL6788496 | 0.83 | CCNA2 (0.71) | CCNA2CDK2CCNA1 | |
| SCHEMBL6790199 | 0.83 | CCNA2 (0.71) | CCNA2CDK2CCNA1 | |
| SCHEMBL6790974 | 0.83 | CCNA2 (0.71) | CCNA2CDK2CCNA1 | |
| SCHEMBL6786755 | 0.83 | CCNA2 (0.71) | CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-17 | — | — | US | disclosed |
| EP-4342540-A2 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | Aurigene Oncology Limited (IN) | 2024-03-27 | — | — | EP | disclosed |
| EP-3302448-B1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2023-10-25 | — | — | EP | disclosed |
| EP-3302448-B1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2023-10-25 | — | — | EP | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-20220098156-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-31 | — | — | US | disclosed |
| US-11174232-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-16 | — | — | US | disclosed |
| US-11174232-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-16 | — | — | US | disclosed |
| US-20200262793-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-08-20 | — | — | US | disclosed |
| US-10689347-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-06-23 | — | — | US | disclosed |
| US-10689347-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-06-23 | — | — | US | disclosed |
| US-20180362471-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-12-20 | — | — | US | disclosed |
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| EP-3302448-A1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193939-A1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016193939-A1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | CCNA2 30/4885CDK2 20/4885CCNA1 37/4885 |
| US-11174232-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | CCNA2 30/4885CDK2 20/4885CCNA1 37/4885 |
| US-20180362471-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK17, CDK1 | CCNA2 31/4885CDK2 19/4885CCNA1 38/4885 |
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK17, CDK1 | CCNA2 31/4885CDK2 19/4885CCNA1 38/4885 |
| US-10689347-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | CCNA2 30/4885CDK2 20/4885CCNA1 37/4885 |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | CCNA2 30/4885CDK2 20/4885CCNA1 37/4885 |
| US-20200262793-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | CCNA2 30/4885CDK2 20/4885CCNA1 37/4885 |
| US-20220098156-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | CCNA2 30/4885CDK2 20/4885CCNA1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.